Carfilzomib, Dexamethasone, and Daratumumab Myeloma Treatment Alternative
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, talks about the use of carfilzomib, dexamethasone, and daratumumab as a cheaper alternative for treating relapsed or refractory multiple myeloma as seen in the ALLG MM018/ AMN002 study.
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, a consultant clinical and laboratory hematologist at St. Vincent’s Hospital in East Melbourne, Australia talks about the use of carfilzomib (Kyprolis), dexamethasone, and daratumumab (Darzalex) as a cheaper alternative for treating relapsed or refractory multiple myeloma as seen in the ALLG MM018/ AMN002 study.
Lenalidomide and bortezomib are often used to treat patients with newly-diagnosed multiple myeloma. However, many patients progress while on these agents or discontinue them due to toxicity. According to Quach, not all jurisdictions are able to afford the higher cost combination of carfilzomib and lenalidomide. Therefore, a more affordable yet equally effective alternative must be found.
The study, which was presented at the 62nd American Society of Hematology Meeting and Exposition, is a collaboration between the Asian Myeloma Network and the Australian Leukemia Myeloma Group.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
